“‘While the paper provides solid evidence that COPAs can raise prices, lower the quality of care, and create access problems, the FTC can’t do much more than recommend that states stop using them,’ said Richard Scheffler, a health economist and policy professor at the University of California, Berkeley.”
Read the full article here.